Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GONZALEZ-CRESPO, M. R.
Right arrow Articles by RODRIGUEZ-VALVERDE, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GONZALEZ-CRESPO, M. R.
Right arrow Articles by RODRIGUEZ-VALVERDE, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 British Society for Rheumatology

research-article

MENSTRUAL DISORDERS IN GIRLS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH CYCLOPHOSPHAMIDE

M. R. GONZALEZ-CRESPO*, J. J. GOMEZ-REINO*,, R. MERINO{dagger}, E. CIRUELO*, F. J. GOMEZ-REINO*, R. MULEY*, J. GARCIA-CONSUEGRA{dagger}, V. PINILLOS{ddagger} and V. RODRIGUEZ-VALVERDE{ddagger}

Department of Rheumatology and Paediatrics Santander, Spain
*Hospital Doce de Octubre Santander, Spain
{dagger}Hospital La Paz Madrid, Spain
{ddagger}Department of Rheumatology, Hospital Marques de Valdecilla Santander, Spain

Correspondence to: Correspondence to: J. J. Gömez-Reino, Department of Rheumatology, Hospital Doce Octubre, 28041 Madrid, Spain.

To study the ovarian toxicity associated with cyclophosphamide in girls with systemic lupus erythematosus (SLE), we retrospectively reviewed the charts of 30 SLE girls aged 16 yr or younger at diagnosis, followed at three university hospitals. Gynaecological history was extracted from the charts or obtained prospectively. Ten had not received cyclophosphamide therapy, six were treated with daily oral cyclophosphamide, 10 with intravenous pulses and four with daily oral and intravenous pulses. Median oral cyclophosphamide dose was 38 g (inter-quartile range 75) and median intravenous dose 12.95 g (inter-quartile range 6.2). Six girls had oligomenorrhoea (20%) and one amenorrhoea (3%). Two treated with oral cyclophosphamide had oligomenorrhoea (33%) and one amenorrhoea (17%), two treated with both oral and intravenous pulses had oligomenorrhoea (50%), and none of those treated with intravenous pulses alone had menstrual disturbances (50% oral vs 0% intravenous pulses; P = 0.016). Girls who had menstrual disturbances had received higher doses of cyclophosphamide than those who did not (medians: 63 vs 15 g; P < 0.05). In summary, menstrual disturbances in SLE girls treated with cyclophosphamide are related to the total dose and perhaps to the administration method.

KEY WORDS: Systemic lupus erythematosus, Menstrual disorders, Cyclophosphamide, Amenorrhoea


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
C.A.A. Silva, M.O. Hilario, M.V. Febronio, S.K. Oliveira, M.T. Terreri, S.B. Sacchetti, F.R. Sztajnbok, R. Marini, M.V. Quintero, B.E. Bica, et al.
Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study
Lupus, July 1, 2007; 16(7): 531 - 536.
[Abstract] [PDF]

Home page
 LupusHome page
A Tincani, D Bompane, E Danieli, and A Doria
Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome)
Lupus, March 1, 2006; 15(3): 156 - 160.
[Abstract] [PDF]

Home page
 LupusHome page
D C. de Sousa, M M d. C. Medeiros, V S T. Viana, and R M S. Mota
Anti-corpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis
Lupus, August 1, 2005; 14(8): 618 - 624.
[Abstract] [PDF]

Home page
 LupusHome page
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas
Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus
Lupus, December 1, 2004; 13(12): 887 - 890.
[PDF]

Home page
 Rheumatology (Oxford)Home page
R. M. Laxer
Long-term toxicity of immune suppression in juvenile rheumatic diseases
Rheumatology, August 1, 1999; 38(8): 743 - 746.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
R Sathananthan and J David
The adolescent with rheumatic disease
Arch. Dis. Child., October 1, 1997; 77(4): 355 - 358.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.